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Reduced Nicotinamide Adenine Dinucleotide
Phosphate Oxidase-Derived Superoxide and
Vascular Endothelial Dysfunction in Human Heart Failure
Rafał Dworakowski, MD, PHD,* Simon Walker,* Aziz Momin, FRCS,* Jatin Desai, FRCS,*
Ahmed El-Gamel, FRCS,* Olaf Wendler, MD, PHD,* Mark T. Kearney, MD, FRCP,†
Ajay M. Shah, MD, FMEDSCI*
London and Leeds, United Kingdom
Objectives We investigated the role of reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in endothe-
lial dysfunction in human heart failure.
Background Vascular endothelial dysfunction in human heart failure contributes to increased tone, exercise limitation, and
dysregulation of venous capacitance and vascular volume. The NADPH oxidases (Nox) are an important source
of oxidative stress, but their role in the endothelial dysfunction of human heart failure remains unknown.
Methods Endothelium-dependent and -independent vasorelaxation were assessed in saphenous vein segments obtained
from consecutive patients with heart failure (n  19) or normal left ventricular function (control; n  35) under-
going coronary artery bypass graft. Saphenous vein superoxide production was measured by lucigenin-enhanced
chemiluminescence and messenger ribonucleic acid expression of relevant transcripts quantified by real-time
polymerase chain reaction.
Results Heart failure patients had significantly worse endothelial function than control subjects (15.2  3% vs. 40.5 
8.4% relative relaxation; p  0.05), elevated C-reactive protein (CRP) levels (8.6  2.7 mg/l vs. 2.6  0.4 mg/l;
p  0.05), over 2-fold higher NADPH-dependent superoxide generation (p  0.05), and significantly higher ex-
pression of the Nox4 isoform and regulatory subunit p67phox. Superoxide levels were positively correlated with
New York Heart Association functional class (r  0.684; p  0.05) and CRP (r  0.501; p  0.005; n  32).
Conclusions Venous endothelial dysfunction in human heart failure is associated with increased Nox-derived superoxide
generation. Inflammatory mechanisms may be involved in the increased reactive oxygen species generation.
(J Am Coll Cardiol 2008;51:1349–56) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.12.033v
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dhe endothelium modulates vascular tone through the
egulated release of vasodilator agents, notably nitric oxide
NO). Endothelial vasodilator dysfunction in the setting of
uman chronic heart failure (CHF) may contribute to
ncreased arterial tone, increased systemic vascular resis-
ance, and exercise limitation due to inability to sufficiently
ugment skeletal muscle perfusion (1,2). An increase in
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007, accepted December 17, 2007.enous tone may contribute to dysregulation of vascular
olume and increased ventricular preload (3,4). Addition-
lly, endothelial dysfunction is a predictor of adverse out-
ome in CHF patients (5).
A major factor underlying impaired endothelium-
ependent vasorelaxation is a reduction in NO bioavailabil-
ty. Human studies have reported that both acute and
hronic administration of the antioxidant vitamin C im-
roves NO-mediated vasodilatation in CHF (6). These and
ther studies (7,8) suggest that endothelial dysfunction in
uman CHF may result from increased degradation of NO
y reactive oxygen species (ROS). However, the mecha-
isms underlying increased vascular ROS levels in CHF
atients remain to be fully defined.
Potential sources of vascular ROS include the reduced
icotinamide adenine dinucleotide phosphate (NADPH) oxi-
ases (Nox), uncoupled NO synthases (NOS), and xanthine
xidase (9). Among these, in animal models, increased Nox-
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cated in driving endothelial dys-
funct ion in hypertension,
hypercholesterolemia, atheroscle-
rosis, and diabetes (9,10). How-
ever, the role of Nox in vascular
endothelial dysfunction in human
CHF has not been investigated.
Interestingly, increased Nox ex-
pression and activity contributed
to aortic endothelial dysfunction in
experimental models of CHF
(11,12). Increased Nox activity has
been documented in the myocar-
dium of humans with CHF (13).
This study aimed to investi-
gate the role of Nox in endothe-
lial dysfunction in human CHF.
To correlate vasorelaxation with
the expression of different Nox
isoforms and biochemical activ-
ity, we studied ex vivo saphenous
vein segments obtained from pa-
tients with CHF and those with
normal left ventricular (LV)
function undergoing coronary ar-
tery bypass graft (CABG).
ethods
atients. Consecutive patients undergoing CABG at
ing’s College Hospital (London) were considered for
nclusion in the study, which was approved by the local
esearch ethics committee. All subjects provided written
nformed consent. We studied 19 patients with a diagnosis
f CHF based on conventional criteria, i.e., typical clinical
ymptoms of exertional breathlessness plus echocardio-
raphic evidence of impaired LV systolic function (LV
jection fraction [EF] 45%). Thirty-five patients without
ny symptoms of heart failure and with LV EF 50% were
ncluded as control subjects.
Saphenous veins were harvested without distension and
ith minimal tissue handling. Immediately after collection,
art of the vein was placed in ice-cold pre-oxygenated
hysiological buffer for organ bath studies, and a portion
as snap-frozen in liquid nitrogen and stored at 80°C for
essenger ribonucleic acid isolation or superoxide assays.
lasma assays. Fasting blood samples were obtained before
urgery for measurement of serum total cholesterol, high-
ensity lipoprotein (HDL) cholesterol, low-density lipopro-
ein (LDL) cholesterol, triglycerides, glucose, and creati-
ine. Serum samples were stored at 80°C until analysis.
-reactive protein (CRP) was measured using a high-
ensitivity turbidimetric immunoassay (Wako Chemicals,
euss, Germany) on a Cobas Mira Analyser (Roche Diag-
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
CHF  chronic heart failure
CRP  C-reactive protein
DPI  diphenyleneiodonium
EF  ejection fraction
IL  interleukin
LV  left
ventricle/ventricular
NADPH  nicotinamide
adenine dinucleotide
phosphate
NO  nitric oxide
NOS  nitric oxide
synthase
Nox  nicotinamide
adenine dinucleotide
phosphate oxidase(s)
ROS  reactive oxygen
species
SNP  sodium
nitroprusside
TNF  tumor necrosis
factorostics, Burgess Hill, U.K.). The lowest CRP concentration
vhat was detectable was 0.2 mg/l. The coefficient of variation
CV) for within-batch variability was 3.1% at 5.0 mg/l.
umor necrosis factor (TNF)- and interleukin (IL)-6 were
easured using a commercial enzyme-linked immunosor-
ent assay (R&D Systems, Minneapolis, Minnesota). The
V for TNF- was 9% and for IL-6 9%.
asomotor studies. Saphenous vein rings were suspended
n organ baths containing Krebs-Henseleit solution (com-
osition, mmol/l: NaCl 119, KCl 4.7, KH2PO4 1.18,
aHCO3 25, MgSO4 1.19, CaCl2 2.5, glucose 11.0) at
7°C, and bubbled with 95% O2/5% CO2 to maintain a pH
f 7.4 (14). Resting tension was set at 3 g, and after 45 min
quilibration maximal contractile response to 80 mmol/l
Cl was assessed followed by a cumulative dose-response
urve to phenylephrine (1 nmol/l to 1 mmol/l). Relaxation
esponses to cumulative addition of acetylcholine (1 nmol/l
o 0.01 mmol/l) and sodium nitroprusside (SNP) (0.1
mol/l to 0.1 mmol/l) were studied in rings pre-constricted
o 70% maximal phenylephrine tension.
ascular ROS. Superoxide production was measured in
ein homogenates using lucigenin-enhanced chemilumines-
ence in a 96-well microplate luminometer, with NADPH
300 mol/l) and dark-adapted lucigenin (5 mol/l) (15).
uperoxide production was expressed as arbitrary light units
ver 20 min. In some experiments, one of the following was
re-incubated for 15 min to assess potential sources of
uperoxide production: a cell-permeable superoxide scaven-
er Tiron (4,5-dihydroxy-1,3-benzene disulfonic acid, 20
mol/l), diphenyleneiodonium (DPI, a flavoprotein inhib-
tor, 10 mol/l), L-NAME (NG-nitro-L-arginine methyl
ster, an NOS inhibitor, 100 mol/l), allopurinol (a xan-
hine oxidase inhibitor, 100 mol/l), or rotenone (a complex
mitochondrial electron chain inhibitor, 2 mol/l).
eal-time polymerase chain reaction (PCR). Ribonucleic
cid was isolated using RNeasy Fibrous Tissue Kit (Qiagen,
rawley, U.K.). Complementary DNA was synthesized using
mniscript kit (Qiagen) and random decamers. Real-time
CR was performed with an Abi Prism 7700 machine (Ap-
linical Characteristics of Patients
Table 1 Clinical Characteristics of Patients
Control (n  35) Heart Failure (n  19)
Age, yrs 63 8 65 6
Gender (male:female) 35:0 18:1
Smoking, n (%) 24 (69) 15 (79)
Hypertension, n (%) 28 (80) 14 (74)
Diabetes mellitus, n (%) 6 (17) 8 (42)*
Hypercholesterolemia, n (%) 28 (80) 16 (84)
Previous MI, n (%) 16 (46) 16 (84)*
Non–Q-wave MI , n (%) 11 (31) 1 (5)*
Q-wave MI, n (%) 5 (14) 15 (79)*
Renal impairment, n (%) 4 (11) 7 (37)*
Systolic blood pressure, mm Hg 143 4 129 6
Diastolic blood pressure, mm Hg 76 2 72 3
ata are mean  SEM where not otherwise specified. *p  0.05 by chi-square test for categoric
ariables and unpaired Student t test for continuous variables.
MI  myocardial infarction.
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April 8, 2008:1349–56 NADPH Oxidase and Endothelial Function in CHFlied Biosystems, Foster City, California) using Sybr Green
nd universal thermal cycling parameters. Expression levels
ere determined using standard curves from known amounts
f template and normalized to -actin. Primer sequences were:
ox1 forward CACAAGAAAAATCCTTGGGTCAA,
everse GACAGCAGATTGCGACACACA; Nox2 for-
ard CAAGATGCGTGGAAACTACCTAAGAT, re-
erse CCCTGCTCCCACTAACATCA; Nox4 forward
AGCAAGATACCGAGATGAGGA, reverse GTA-
AGGCTGTGATCATGAGGAATAG; eNOS forward
AACAGCACAAGAGTTATAAGATCCG, reverse
CACTGTCTGTGTTACTGGACTCCT; p67phox
orward GCACTACAAGTACACGGTAGTCATGAA,
everse CGAGGCCGATAGCTCAGCT; p47phox for-
ard TTCAAGGTGCGCCCTGAT, reverse TGAT-
TCTGTCGCGGTACTCTT; and -actin forward
CGAGAAGATGACCCAGATCA, reverse TC-
CCGGAGTCCATCACGAT.
The investigators undertaking vasomotor studies, superoxide
eneration, and real-time PCR were blinded to study groups.
Figure 1 Plasma Levels of Inflammatory Markers CRP, IL-6, an
(A) C-reactive protein (CRP) levels in control versus heart failure groups; *p  0.0
(NYHA) functional class. The linear regression was adjusted for diabetes and renatatistics. Analyses were performed using the SPSS 13
tatistical package (SPSS Inc., Chicago, Illinois). Data
ere expressed as mean  SEM. Baseline comparisons
etween patient groups or treatments were performed
sing chi-square test, unpaired Student t test, 1-way
nalysis of variance followed by a Scheffe test or a
onparametric Mann-Whitney test as appropriate. Non-
ormally distibuted data were log transformed before t
ests. Levene test was used to test homogeneity of
ariance. Variables with evidence of heterogeneity of
ariance were analyzed with nonparametric tests. Corre-
ation between continuous variables was assessed by
imple linear Pearson correlation and between continuous
ariables and ordinal variables by linear regression. Lo-
istic regression analysis was used to assess the impact of
ultiple variables on vascular superoxide production. We
uilt a stepwise model of potential influencing variables
n superoxide release and then carried out the hierarchic
ackward elimination process to determine the best fit. p
0.05 was considered to be statistically significant.
- in Subjects With or Without Heart Failure
ann-Whitney test. (B) CRP levels by New York Heart Association
e. (C) Interleukin (IL)-6 levels. (D) Tumor necrosis factor (TNF)- levels.d TNF
5 by M
l failur
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NADPH Oxidase and Endothelial Function in CHF April 8, 2008:1349–56esults
atient characteristics. Clinical characteristics are shown
n Table 1. The CHF patients had significantly reduced EF
37.5  1.7%), whereas all control subjects had EF 50%.
he precise value of EF 50% was not available in all
ontrol subjects. The 2 groups were well matched for age,
ender, smoking status, hypertension, and hypercholester-
lemia. Extent of coronary artery disease was also similar in
he control and CHF groups: 2-vessel disease 11% vs. 10%,
-vessel disease 51% vs. 63%, and left main disease 37% vs.
6%, respectively. As expected, the CHF group had more
atients with diabetes, previous myocardial infarction, and
mpaired renal function (creatinine 105 mmol/l). Fasting
holesterol and triglyceride levels were similar in the 2
roups (data not shown).
Significantly more CHF than control patients were tak-
ng angiotensin-converting enzyme inhibitors and/or
ngiotensin-receptor blockers (68% vs. 40%) and diuretics
63% vs. 14%); both p  0.05. However, the proportion of
atients taking other medications was similar in the control
nd CHF groups: antiplatelet agents 83% and 89%, beta-
lockers 77% and 53%, statins 91% and 89%, and antian-
inal agents (nitrates, calcium antagonists) 89% and 68%,
espectively.
nflammatory markers. The CRP levels were significantly
igher in CHF patients than in control subjects and
orrelated with clinical severity of heart failure as assessed by
ew York Heart Association (NYHA) functional class, even
fter adjusting for diabetes and renal failure (Figs. 1A and 1B).
he TNF- and IL-6 levels tended to be higher in the CHF
roup, but did not achieve significance (Figs. 1C and 1D).
here was a significant positive correlation between IL-6 and
RP levels (r  0.627; p  0.0001), as expected.
asomotor function. Mean vasodilator responses to ace-
ylcholine and to SNP were not significantly different
etween the 2 patient groups as a whole using nonlinear
egression (Figs. 2A and 2B), but both varied markedly
mong patients in each group. To assess endothelium-
ependent relaxation relative to the smooth muscle response
o nonendothelial NO per se (i.e., SNP), we normalized the
aximal acetylcholine response by the maximal SNP re-
ponse in each ring. Figure 2C shows that the relative
ndothelium-dependent relaxation was significantly lower
n CHF compared with control subjects. This difference
emained significant if patients with diabetes were excluded
37.2 8.8% vs. 17.0 4.7% control vs. CHF, respectively;
 0.05).
ascular ROS. Superoxide generation was significantly
reater in saphenous veins of CHF patients compared with
ontrol subjects (Fig. 3A) and remained greater in the CHF
roup after exclusion of diabetics (2.1 0.3 ILU vs. 4.5 0.7
LU control vs. CHF, respectively; p  0.05). There was a
ignificant correlation between the level of superoxide pro-
uction and NYHA functional class by linear regression
p  0.0001) (Fig. 3B), which was independent of diabetes er renal failure. However, we did not find a significant
orrelation between superoxide generation and EF or
Figure 2 Vasomotor Function in Saphenous Vein
Segments From Control and Heart Failure Groups
(A) Mean concentration-response relationship for acetylcholine (ACh). (B) Mean
concentration-response relationship for sodium nitroprusside (SNP). (C) Rela-
tive endothelial-dependent relaxation (maximum response to ACh normalized by
the maximal response to SNP). *p  0.05 by Mann-Whitney test.ndothelial-dependent relaxation (data not shown). Super-
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April 8, 2008:1349–56 NADPH Oxidase and Endothelial Function in CHFxide production in both groups was virtually inhibited by
PI or Tiron but unaffected by L-NAME, allopurinol, or
otenone (Fig. 3C), consistent with Nox being the main
ource.
We investigated potential factors responsible for the
ncreased superoxide levels using a multiple logistic regres-
ion model with superoxide production as the dependent
ariable and NYHA functional class, CRP, renal failure,
iabetes, hypertension, and hypercholesterolemia as covari-
tes. Only NYHA functional class and CRP levels corre-
ated with superoxide (p 0.005; n 32). Figure 3D shows
he correlation between CRP levels and vascular superoxide.
xpression of Nox subunits and eNOS. To investigate
he possible contributors to increased saphenous vein Nox
ctivity, we analyzed messenger ribonucleic acid (mRNA)
xpression of the oxidase catalytic subunits Nox1, Nox2, and
ox4 and the regulatory subunits p47phox and p67phox.
he Nox4 expression was significantly higher in the CHF
ompared with control group, and Nox2 tended to be higher
ut not significantly (Figs. 4A and 4B). The Nox1 expres-
Figure 3 Superoxide Production by Human Saphenous Veins Fr
(A) Superoxide production by lucigenin-enhanced chemiluminescence. *p  0.05
ciation (NYHA) functional class using a linear regression model adjusted for diabe
tion in the control and heart failure groups. *p  0.05 by analysis of variance follo
group or the heart failure group. DPI  diphenyleneiodonium; L-NAME  NG-nitro-L
(CRP) levels; Pearson correlation: r  0.501; p  0.05.ion was below the level of detection in virtually all patients pn both groups. The level of p67phox expression was
ignificantly higher in the CHF compared with the control
roup, whereas p47phox levels were similar in the 2 groups
Figs. 4C and 4D). We found no difference in eNOS
RNA expression level between the 2 groups (data not
hown).
iscussion
mpaired endothelium-dependent vasorelaxation has been
emonstrated in many arterial vascular beds in vivo in
atients with CHF and contributes to several aspects of
isease pathophysiology (1,2). A reduction in NO bioavail-
bility secondary to increased inactivation by superoxide is a
ajor etiologic factor in this dysfunction, but the ROS
ources that are responsible in human CHF remain incom-
letely understood. In the present study, we found that
elative endothelial-dependent relaxation was impaired in
eins of CHF patients compared with control subjects,
nalogous to previous findings in arterial beds. More im-
atients With and Without Heart Failure
n-Whitney test. (B) Relationship between superoxide and New York Heart Asso-
d renal failure. *p  0.05. (C) Effect of various inhibitors on superoxide produc-
y Scheffe test, to test for differences among interventions in either the control
e methyl ester. (D) Relationship between superoxide and C-reactive proteinom P
by Man
tes an
wed b
-argininortantly, the endothelial dysfunction was associated with
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NADPH Oxidase and Endothelial Function in CHF April 8, 2008:1349–56n increase in Nox-derived superoxide generation, which
as accompanied by increased expression of the Nox4
soform and the oxidase regulatory subunit p67phox and
as correlated with elevated CRP levels, suggesting that it
ay be driven by inflammatory activation.
Several ROS sources may potentially contribute to endo-
helial dysfunction in CHF, including xanthine oxidase,
ncoupled NOS, Nox, and mitochondria (9). In the exper-
mental setting, increased Nox-derived ROS generation is
nvolved in the development of endothelial dysfunction in
any different conditions (9,10) and has been implicated in
xperimental heart failure (11,12). Recent in vivo studies
n CHF patients provide quite good evidence that xanthine
xidase-derived ROS may contribute to endothelial dys-
unction in the forearm arterial bed (7,8), but a possible role
f Nox was not investigated. Interestingly, increased Nox-
erived ROS not only contribute directly to endothelial
ysfunction but may also play a key role in triggering further
OS production through the conversion of xanthine dehy-
rogenase to xanthine oxidase and the uncoupling of NOS
econdary to oxidative degradation of the cofactor tetrahy-
robiopterin (9). Therefore, an initial increase in Nox-
erived ROS may be a key factor driving ROS production
y other sources. In the present study, we found clear
vidence of increased Nox activity in saphenous veins of
Figure 4 Expression of Nox Isoforms by Real-Time Polymerase
Reaction in Human Saphenous Veins From Patients W
(A) Nox2 expression; (B) Nox4 expression; (C) p47phox expression; (D) p67phox
acid; Nox  nicotinamide adenine dinucleotide phosphate oxidase.HF patients compared with control subjects. The sADPH-dependent ROS generation was inhibited by DPI
ut not by inhibitors of NOS, xanthine oxidase, or mito-
hondrial complex I, consistent with Nox as the source. We
lso noted a progressive increase in Nox activity with
ncreasing NYHA functional class.
The potential mechanisms that may activate Nox are
mportant to elucidate to understand why and how it
ontributes to endothelial dysfunction in CHF. Human
HF is well recognized to be associated with elevated
nflammatory markers such as CRP, IL-6, and TNF-, and
he levels of these markers correlate with NYHA functional
lass, hospitalization rate, and survival (16). Cytokines such
s TNF- may be involved in the pathogenesis of endothe-
ial dysfunction by modulating the balance between produc-
ion of NO and vasoconstrictors (17), but are also potent
ctivators of vascular Nox (15,18). C-Reactive protein is
lso reported to have direct effects on endothelial function
y enhancing Nox-derived superoxide generation (19). In
he present study, we confirmed that CRP levels were
ignificantly elevated in CHF patients, with a similar trend
or IL-6 and TNF-. More importantly, there was a strong
nd independent correlation between CRP levels and Nox
ctivity, suggesting that inflammatory mechanisms may be
esponsible for activating Nox in CHF.
The Nox isoforms are now well recognized as major ROS
nd Without Heart Failure
ssion. *p  0.05 by unpaired Student t test. mRNA  messenger ribonucleicChain
ith a
expreources involved in the genesis of endothelial dysfunction as
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April 8, 2008:1349–56 NADPH Oxidase and Endothelial Function in CHFell as pathological redox signaling in many diseases (9).
he prototypic Nox first described in neutrophils contains a
ox2 (or gp91phox) subunit which is responsible for
atalyzing electron transfer from NADPH to molecular O2,
hereby generating superoxide (20). The active Nox2 oxi-
ase complex contains not only Nox2 and its partner
ubunit p22phox but also several regulatory subunits
p47phox, p67phox, Rac), whose association with the oxi-
ase is required for its activation; p67phox is essential for
xidase activation. The Nox2 isoform is now known to be
xpressed also in the endothelium, adventitial fibroblasts,
nd inflammatory cells (9). Recently, other distinct Nox
soforms each encoded by separate genes have been de-
cribed, among which Nox1 and Nox4 are thought to be
mportant in the vasculature, the former mainly in rodent
essels (20). Both Nox2 and Nox4 are expressed in human
essels, and we found that Nox4 mRNA levels were signif-
cantly elevated in the CHF group. Interestingly, Nox4
ctivity is thought to be regulated largely at a transcriptional
evel (20), suggesting that the elevated mRNA levels may
ontribute to increased ROS generation. The Nox4 activity
as also been reported to be increased by inflammatory
timuli such as lipopolysaccharide (21). In contrast to Nox4,
ox2 is largely activated by the regulatory subunits p47phox
nd p67phox, with the latter being directly implicated in
ctivation (20). It is therefore notable that we found a
ignificant increase in p67phox levels, which could contrib-
te to increased Nox2 oxidase activity. The Nox2 levels also
ended to be elevated but not significantly, whereas the level
f Nox1 was very low.
Earlier human studies reported a role of Nox-derived
OS in endothelial dysfunction in patients with coronary
rtery disease and diabetes as well as an association with risk
actors for coronary disease (22,23). Although all subjects in
he present study had coronary artery disease and most had
t least 1 risk factor for atherosclerosis, the groups with and
ithout CHF were well matched for these factors, apart
rom diabetes which was more prevalent in the CHF group.
owever, the relationship between superoxide production
nd heart failure was found to be independent of diabetes,
nd the difference between groups remained after exclusion
f patients with diabetes. In multiple regression analysis,
RP and NYHA functional class were the only indepen-
ent factors that correlated with superoxide production. It is
orth noting that the majority of subjects studied were
eceiving medications, namely, statins and antagonists of
he renin-angiotensin system, that are known to reduce Nox
ctivity and improve endothelial function (9). Therefore, it
s possible that the levels of superoxide could be higher and
ndothelial dysfunction even worse in CHF patients not on
hese drugs. However, it should also be noted that numer-
us factors, including several that reduce NO production,
ay be involved in endothelial dysfunction, so that the
urrent findings do not exclude a role for such factors.
In summary, the present study indicates for the first timehat increased Nox activity contributes to elevated superox-
1de production and vascular endothelial dysfunction in
uman CHF and suggests that increased inflammatory
ctivation may be an etiologic factor. Because the present
tudy was undertaken in saphenous veins, determining
hether there is a similar increase in Nox activity in arteries
ould require direct investigation. However, earlier work
uggested that there was a close correlation between arterial
nd venous Nox expression in humans, possibly because of
ommon systemic influences (24). The present results sug-
esting that inflammatory activation may drive the changes
n superoxide production are consistent with this idea.
lthough no direct comment can be made about the arterial
irculation, venous endothelial dysfunction may be im-
ortant in the pathophysiology of human CHF by
egulating venous capacitance, venous return, and ven-
ricular preload (4,25).
eprint requests and correspondence: Prof. Ajay M. Shah,
ardiovascular Division, James Black Centre, King’s College
ondon, 125 Coldharbour Lane, London SE5 9NU, U.K. E-mail:
jay.shah@kcl.ac.uk.
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